Teva Pharmaceutical Industries (TEVA) closed at $40.62 on October 21, 2026, down 0.6% from the previous close, on volume of 4,263,094 shares (30-day average 5,681,373).
Data as of October 21, 2026.
Alvotech wins FDA nod for new manufacturing process for Humira biosimilar
Seeking Alpha News (Tue, 20-Oct 8:02 AM ET)
Globe Newswire (Tue, 20-Oct 8:00 AM ET)
Teva to Host R&D Day on Wednesday, November 11 in New York City
Globe Newswire (Mon, 12-Oct 5:45 PM ET)
Market Chameleon (Fri, 9-Oct 7:33 AM ET)
Globe Newswire (Fri, 9-Oct 7:00 AM ET)
Globe Newswire (Fri, 2-Oct 8:00 AM ET)
Globe Newswire (Fri, 2-Oct 8:00 AM ET)
Globe Newswire (Wed, 30-Sep 4:32 PM ET)
Globe Newswire (Mon, 28-Sep 4:00 PM ET)
Teva Sets Nov. 3 Q3 2026 Results Call, Putting 8:00 a.m. ET on Investors’ Calendars
Market Chameleon (Thu, 24-Sep 4:42 AM ET)
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries trades on the NYSE stock market under the symbol TEVA.
As of October 22, 2026, TEVA stock price declined to $40.01 with 1,952,171 million shares trading.
TEVA has a beta of 0.85, meaning it tends to be less sensitive to market movements. TEVA has a correlation of 0.07 to the broad based SPY ETF.
TEVA has a market cap of $46.66 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries reported $4 billion in Revenue and $.02 earnings per share. This beat revenue expectation by $74 million and missed earnings estimates by -$.39.
In the last 3 years, TEVA traded as high as $42.02 and as low as $8.06.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EIS, WCMI, EFG.
TEVA has outperformed the market in the last year with a price return of +110.7% while the SPY ETF gained +15.0%. TEVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +27.6% and +2.1%, respectively, while the SPY returned +2.4% and -1.7%, respectively.
TEVA support price is $39.81 and resistance is $41.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA shares will trade within this expected range on the day.
